Navigation Links
Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/12/2009

ept to design or successfully carry out additional safety studies in support of potential resubmission of an NDA for Intermezzo®; the sufficiency of the content in the planned resubmission in support of the Intermezzo® NDA; a decision by Purdue to not devote time or resources to support the approval of Intermezzo® or to terminate the Purdue collaboration agreement, even if the Intermezzo® NDA is approved; unforeseen expenses related to efforts in support of FDA approval, general and administrative expenses; other research and development expenses and the business of Transcept generally; dependence on third parties to manufacture Intermezzo®; obtaining, maintaining and protecting the intellectual property incorporated into Intermezzo®; other difficulties or delays in the commercialization of Intermezzo®; and the ability of Transcept to obtain additional funding, if needed, to support its business activities. These and other risks are described in greater detail in the "Risk Factors" section of Transcept periodic reports filed with the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments Transcept may enter into or make. Transcept does not assume any obligation to update any forward-looking statements, except as required by law.

FINANCIAL TABLES FOLLOW



    Transcept Pharmaceuticals, Inc.
    Statements of Operations
    (Unaudited)

                            Three Months Ended          Nine Months Ended
                               September 30,              September 30,
                            ------------------          -----------------
                             2009         2008          2009          2008
                             ----         ----          ----          ----
    Revenue:
      License fee
       reve
'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
2. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
3. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
4. Transcept Pharmaceuticals to Report First Quarter 2009 Results
5. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
6. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
7. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
8. Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
9. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
10. Endo Pharmaceuticals and LecTec Settle Patent Dispute
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... FAIRFIELD, N.J. , July 30, 2015 /PRNewswire/ ... Ferrer, completed the second Phase III clinical study ... development for impetigo.  Medimetriks owns the exclusive U.S. ... The global trial, conducted at 44 centers with ... and pediatric patients aged 2 months and older ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... received written notification on May 25, 2012, from the ... York Stock Exchange LLC ("NYSE"), that the staff had ... of the Company and file a delisting application with ...
... Today the House passed H.R. 5651, its version ... including important provisions to mitigate drug shortages, most notably ... the world,s largest professional society concerned with the causes ... members who specialize in blood cancers such as leukemia, ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE 2American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA) 2
(Date:7/30/2015)... ... July 30, 2015 , ... The ... BioPharma, Inc. are pleased to announce that data standards for clinical research in ... on the CDISC website . These three Therapeutic Area (TA) standards were ...
(Date:7/30/2015)... ... July 30, 2015 , ... In an effort to provide ... Aggarwal is making a change in his practice. , The decision will also allow ... 2015, Dr. Aggarwal will be transferring his in-patient admissions to the hospitalists at East ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating ... Lines ." It's for women interested in improving their love lives using specific ... which officially launched to the public early this morning, has drawn praise from ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... In a ... clients at Serenity Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing ... one of its most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... is the recipient of three awards in the Service Industry Advertising Awards 12th ... for Choptank Transport, KRM Development Corporation and University of Maryland Shore Regional Health. ...
Breaking Medicine News(10 mins):Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3
... the all-natural weight management program, opened in Ottawa with the ... began their weight-loss journey on the Smart for Life(TM) program ... for 6 family members. As friends and relatives joined the ... exciting business opportunity. , "Smart for Life(TM) is ...
... and services company focused on global eClinical solutions for the clinical ... studies from European Sponsor clients. These new studies will seek to ... as the Indian subcontinent. , "We ... to be a direct result of our continued hard work in ...
... ... and CEO of Abraxis Health, will receive the Adaptive Business Leaders Organization,s 2009 ... Awards Event on October 28, in Newport Beach. , ... Santa Ana, CA (PRWEB) October ...
... ... launch of their "Tats for Tatas" fundraising campaign that will take place ... the company,s concerted efforts to raise awareness and funds for Breast Cancer ... the company will be donating 10% of all proceeds from sales throughout ...
... Pa., Oct. 15 Herley Industries, Inc. (Nasdaq: HRLY ... Fiscal Year ended August 2, 2009. , Fourth Quarter ... quarter of fiscal 2009 were $43.0 million compared to $37.9 ... fourth quarter of fiscal 2009, the Company recorded several significant ...
... Minnesota Nurses Point to Benefits for Patients, Nurse Staffing and ... A new Senate bill introduced today by Sen. Al ... of RNs in hospitals and other health care facilities, but ... transported and moved in the safest way possible, all while ...
Cached Medicine News:Health News:Smart for Life(TM) Center Opens in Ottawa 2Health News:DATATRAK Announces the Award of New Studies from European Pharmaceutical Clients 2Health News:DATATRAK Announces the Award of New Studies from European Pharmaceutical Clients 3Health News:Patrick Soon-Shiong, World Renowned Healthcare Visionary & Philanthropist, to Receive ABL's Leadership Award & Make Keynote Presentation, October 28, in Newport Beach 2Health News:Patrick Soon-Shiong, World Renowned Healthcare Visionary & Philanthropist, to Receive ABL's Leadership Award & Make Keynote Presentation, October 28, in Newport Beach 3Health News:Patrick Soon-Shiong, World Renowned Healthcare Visionary & Philanthropist, to Receive ABL's Leadership Award & Make Keynote Presentation, October 28, in Newport Beach 4Health News:Atomic Tattoos Announces "Tats for Tatas" October Fundraising Event to Benefit Local Breast Cancer Research 2Health News:Herley Reports Fourth Quarter and Year-End Results 2Health News:Herley Reports Fourth Quarter and Year-End Results 3Health News:Herley Reports Fourth Quarter and Year-End Results 4Health News:Herley Reports Fourth Quarter and Year-End Results 5Health News:Herley Reports Fourth Quarter and Year-End Results 6Health News:Herley Reports Fourth Quarter and Year-End Results 7Health News:Herley Reports Fourth Quarter and Year-End Results 8Health News:Herley Reports Fourth Quarter and Year-End Results 9Health News:Herley Reports Fourth Quarter and Year-End Results 10Health News:Herley Reports Fourth Quarter and Year-End Results 11Health News:Herley Reports Fourth Quarter and Year-End Results 12Health News:Nation's RNs Hail Sen. Franken's Support for Safe Patient Handling Measure 2
... opticians in a store environment. Optizone ... retail store industry by opticians. Optizone ... for Optizone 2000. It is written ... User friendly screen interfaces make learning ...
This product offers patient, product and practice cash management to ease the strain of practice administration....
... MaximEyes by First Insight is the ... records solution for eye care professionals. ... with Eyefinitys online servicesrequest VSP authorizations, ... MaximEyes offers EMR, scheduling, billing, demographics, ...
... software for eyecare professionals- Winx ... multi-office practice management system, using ... Winx Pro is a complete ... in effectively managing the administrative, ...
Medicine Products: